MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial.

Alice TheadomS Barker-ColloK M JonesP ParmarR BhattacharjeeV L Feigin

Published in: European journal of neurology (2018)

MLC901 was safe and well tolerated post-TBI. This study provided Class I/II evidence that, for patients with mild to moderate TBI, 6 months of MLC901 improved cognitive functioning.

Keyphrases

traumatic brain injury
severe traumatic brain injury
mild traumatic brain injury
mild cognitive impairment
randomized controlled trial
study protocol
white matter
multiple sclerosis